nach oben

Canadian Journal of Anesthesia/Journal canadien d'anesthésie

Erschienen in:

05.02.2016 | Review Article/Brief Review

Medical cannabis: considerations for the anesthesiologist and pain physician

verfasst von: Pierre Beaulieu, MD, PhD, Aline Boulanger, MD, Julie Desroches, PhD, Alexander J. Clark, MD

Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

New regulations are in place at the federal and provincial levels in Canada regarding the way medical cannabis is to be controlled. We present them together with guidance for the safe use of medical cannabis and recent clinical trials on cannabis and pain.

Source

The new Canadian regulations on the use of medical cannabis, the provincial regulations, and the various cannabis products available from the Canadian Licensed Producers were reviewed from Health Canada, provincial licensing authorities, and the licensed producers website, respectively. Recent clinical trials on cannabis and pain were reviewed from the existing literature.

Principal findings

Health Canada has approved a new regulation on medical marijuana/cannabis, the Marihuana for Medical Purposes Regulations: The production of medical cannabis by individuals is illegal. Health Canada, however, has licensed authorized producers across the country, limiting the production to specific licenses of certain cannabis products. There are currently 26 authorized licensed producers from seven Canadian provinces offering more than 200 strains of marijuana. We provide guidance for the safe use of medical cannabis. The recent literature indicates that currently available cannabinoids are modestly effective analgesics that provide a safe, reasonable therapeutic option for managing chronic non-cancer-related pain.

Conclusion

The science of medical cannabis and the need for education of healthcare professionals and patients require continued effort. Although cannabinoids work to decrease pain, there is still a need to confirm these beneficial effects clinically and to exploit them with acceptable benefit-to-risk ratios.

ElSohly MA, Gul W. Constituents of cannabis sativa. In: Pertwee RG, editor. Handbook of Cannabis. Oxford: Oxford University Press; 2014 .

Guindon J, Beaulieu P, Hohmann AG. Pharmacology of the cannabinoid system. In: Beaulieu P, Lussier D, Porreca F, Dickenson AH, editors. Pharmacology of Pain. Seattle: IASP Press; 2010 .

Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011; 72: 735-44.CrossRefPubMedPubMedCentral

Hill K. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 2015; 313: 2474-83.CrossRefPubMed

Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical use: a systematic review and meta-analysis. JAMA 2015; 313: 2456-73.CrossRefPubMed

Minister of Justice. Marihuana Medical Access Regulations, SOR/2001-227 (2001). Available from URL: http://laws-lois.justice.gc.ca/PDF/SOR-2001-227.pdf (accessed December 2015).

Court of Appeal for Ontario. R. v. Parker, Canadian Legal Information Institute 5762 (On CA 2000). Available from URL: http://www.ontariocourts.on.ca/decisions/2000//july/parker.pdf (accessed December 2015).

Canadian Centre on Substance Abuse. Marijuana for Medical Purposes. July 2015. Available from URL: http://www.ccsa.ca/Resource%20Library/CCSA-Medical-Purposes-Marijuana-Policy-Brief-2015-en.pdf (accessed December 2015).

Government of Canada. Canada Gazette, Vol 146, no 50, December 15, 2012. Available from URL: http://www.gazette.gc.ca/rp-pr/p1/2012/2012-12-15/html/reg4-eng.html#archived (accessed December 2015).

10.

Government of Canada. Marihuana for Medical Purposes Regulations, SOR/2013-119 (2013). Available from URL: http://www.laws-lois.justice.gc.ca/PDF/SOR-2013-119.pdf (accessed December 2015).

11.

Judgments of the Supreme Court of Canada. R. v. Smith, 2015 34. Available from URL: http://scc-csc.lexum.com/scc-csc/scc-csc/en/item/15403/index.do (accessed December 2015).

12.

Kalan H, Porath-Waller AJ. Clearing the Smoke on Cannabis. Medical use of Cannabis and Cannabinoids. 2014. Available from URL: http://www.ccsa.ca/Resource%20Library/CCSA-Medical-Use-of-Cannabis-2012-en.pdf (accessed December 2015).

13.

College of Physicians and Surgeons of British Columbia. Professional Standards and Guidelines: Marijuana for Medical Purposes. May 5 2015, revised July 30 2015. Available from URL: https://www.cpsbc.ca/files/pdf/PSG-Marijuana-for-Medical-Purposes.pdf (accessed December 2015).

14.

College of Physicians and Surgeons of Alberta. Medical Practice: Marihuana for Medical Purposes. April 3, 2014. Available from URL: http://www.cpsa.ca/standardspractice/marihuana-medical-purposes/ (accessed December 2015).

15.

College of Physician and Surgeons of Saskatchewan. Prescription Review Program: Medical Marihuana. 2013. Available from URL: https://www.cps.sk.ca/CPSS/Programs_and_Services/Prescription_Review_Program.aspx?PrescriptionCCO=4 (accessed December 2015).

16.

College of Physicians & Surgeons. Statement no 187: Marijuana (cannabis) for medical purposes. March 2014. Available from URL: http://cpsm.mb.ca/cjj39alckF30a/wp-content/uploads/st187.pdf (accessed December 2015).

17.

College of Physicians and Surgeons of Ontario. Policy statement #1-15, Marijuana for Medical Purposes. 2015. Available from URL: http://www.cpso.on.ca/CPSO/media/documents/Policies/Policy-Items/Marijuana-for-Medical-Purposes.pdf?ext=.pdf (accessed December 2015).

18.

Collège des Médecins du Québec. Guidelines concerning the prescription of dried cannabis for medical purposes. April 2014, updated May 2015. Available from UR: http://www.cmq.org/publications-pdf/p-1-2014-04-01-en-directives-concernant-ordonnance-cannabis-seche-fins-medicales.pdf?t=1445313262790 (accessed December 2015).

19.

College of Physicians and Surgeons of New Brunswick. Guidelines, Medical Marijuana. April 2014. Available from URL: https://www.cpsnb.org/english/Guidelines/MedicalMarijuana.htm (accessed December 2015).

20.

College of Physicians and Surgeons of Nova Scotia. Policy Regarding the Authorization of Marijuana for Medical Purposes. June 26, 2016. Available from URL: https://www.cpsns.ns.ca/DesktopModules/Bring2mind/DMX/Download.aspx?PortalId=0&TabId=129&EntryId=52 (accessed December 2015).

21.

College of Physicians and Surgeons of Prince Edward Island. Policy: Prescribing of Medical Marijuana. May 26, 2014, amended September 2014. Available form URL: http://cpspei.ca/wp-content/uploads/2014/12/Marijuana-Prescribing-revised-May-1313-April-314May-2614-amended-Sept-2014.pdf (accessed December 2015).

22.

College of Physicians and Surgeons of Newfoundland and Labrador. Advisory to the Profession and Interim Guidelines: Marijuana for Medical Purposes. March 2014. Available from URL: http://www.cpsnl.ca/userfiles/file/CPSNL%20%20Medical%20Marihuana%20%20March%202014%20rev%201_0.pdf (accessed December 2015).

23.

Yukon Medical Council. Medical Practice: Marijuana for Medical Purposes. Available from URL: http://www.yukonmedicalcouncil.ca/pdfs/Marijuana_for_Medical_Purposes.pdf (accessed December 2015).

24.

The Canadian Medical Protective Association. Medical marijuana: New regulation, new College guidance for Canadian doctors. May 2014, revised October 2015. Available from URL: https://www.cmpa-acpm.ca/en/legal-and-regulatory-proceedings/-/asset_publisher/a9unChEc2NP9/content/medical-marijuana-new-regulations-new-college-guidance-for-canadian-doctors (accessed December 2015).

25.

Health Canada: Authorized Licensed Producers under the Marihuana for Medical Purposes Regulations, 2015. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/list-eng.php (accessed December 2015).

26.

Health Canada. Daily Amount and Dosing Information Sheet, 2014. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/daily-quotidienne-eng.pdf (accessed December 2015).

27.

McClure EA, Stitzer ML, Vandrey R. Characterizing smoking topography of cannabis in heavy users. Psychopharmacology (Berl) 2012; 220: 309-18.CrossRef

28.

Health Canada. Information for Health Care Professionals, Cannabis (marihuana, marijuana) and the cannabinoids (2013) - Abramovici H. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php#fnb273 (accessed December 2015).

29.

Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 2007; 20: 473-7.CrossRefPubMed

30.

Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26-33.CrossRefPubMed

31.

Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anesth 2006; 53: 769-75.CrossRefPubMed

32.

Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107: 785-96.CrossRefPubMed

33.

Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008; 109: 101-10.CrossRefPubMed

34.

Jefferson DA, Harding HE, Cawich SO, Jackson-Gibson A. Postoperative analgesia in the Jamaican cannabis user. J Psychoactive Drugs 2013; 45: 227-32.CrossRefPubMed

35.

Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 2010; 33: 128-30.CrossRefPubMedPubMedCentral

36.

Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013; 260: 984-97.CrossRefPubMed

37.

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 2013; 14: 136-48.CrossRefPubMedPubMedCentral

38.

Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain 2012; 13: 677-84.CrossRefPubMedPubMedCentral

39.

Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014; 47: 166-73.CrossRefPubMed

40.

Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain 2014; 18: 999-1012.CrossRefPubMed

41.

Turcotte D, Doupe M, Torabi M, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med 2015; 16: 149-59.CrossRefPubMed

42.

Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain 2015; 16: 616-27.CrossRefPubMed

43.

Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 2011; 90: 844-51.CrossRefPubMed

44.

Ware MA, Wang T, Shapiro S, Collet JP; COMPASS study team. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain 2015; 16: 1233-42.

45.

Portenoy R. Treatment of cancer pain. Lancet 2011; 377: 2236-47.CrossRefPubMed

46.

Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15: 139-43.CrossRefPubMed

47.

Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84-9.CrossRefPubMed

48.

Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397-401.CrossRefPubMed

49.

Jochimsen PR, Lawton RL, VerSteeg K, Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 1978; 24: 223-7.CrossRefPubMed

50.

Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39: 167-79.CrossRefPubMed

51.

Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012; 13: 438-49.CrossRefPubMed

52.

Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 2013; 46: 207-18.CrossRefPubMed

53.

College of Family Physicians of Canada. Authorizing Dried Cannabis (Medical Marijuana) for Chronic Pain and Anxiety. Preliminary Guidance, 2014. Available from URL: http://www.cfpc.ca/ProjectAssets/Templates/Resource.aspx?id=7056&terms=marijuana (accessed December 2015).

54.

National Opioid Use Guideline Group (NOUGG). Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Canada, 2010. Available from URL: http://nationalpaincentre.mcmaster.ca/opioid/documents.html (accessed December 2015).

55.

Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005; 10 Suppl A: 44A-6A.

56.

Ware MA, Desroches J. Medical Cannabis and Pain. Pain Clinical Updates, International Association for the Study of Pain, 2014. Available from URL: http://www.iasp-pain.org/PublicationsNews/NewsletterIssue.aspx?ItemNumber=3878 (accessed December 2015).

57.

van der Pol P, Liebregts N, de Graaf R, et al. Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction 2013; 108: 1459-69.CrossRefPubMed

58.

Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med 2012; 42: 1321-8.CrossRefPubMed

59.

Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011; 342: d738.CrossRefPubMedPubMedCentral

60.

van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend 2013; 133: 352-9.CrossRefPubMed

61.

Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014; 113: 187-90.CrossRefPubMed

62.

Casier I, Vanduynhoven P, Haine S, Vrints C, Jorens PG. Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. Acta Cardiol 2014; 69: 131-6.PubMed

63.

Reid PT, Macleod J, Robertson JR. Cannabis and the lung. J R Coll Physicians Edinb 2010; 40: 328-3; quiz 33-4.

64.

Reisfield GM. Medical cannabis and chronic opioid therapy. J Pain Palliat Care Pharmacother 2010; 24: 356-61.CrossRefPubMed

65.

Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem 2013; 59: 478-92.CrossRefPubMed

66.

Neavyn MJ, Blohm E, Babu KM, Bird SB. Medical marijuana and driving: a review. J Med Toxicol 2014; 10: 269-79.CrossRefPubMedPubMedCentral

67.

Hazekamp A, Heerdink ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol 2013; 69: 1575-80.CrossRefPubMed

68.

Pertwee R. Handbook of Cannabis. Oxford: Oxford University Press; 2014 .CrossRef

69.

Woodhams SG, Sagar DR, Burston JJ, Chapman V. The role of the endocannabinoid system in pain. Handb Exp Pharmacol 2015; 227: 119-43.CrossRefPubMed

70.

Lynch ME. The need for a Canadian pain strategy. Pain Res Manag 2011; 16: 77-80.CrossRefPubMedPubMedCentral

71.

Lynch ME, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol 2015; 10: 293-301.CrossRefPubMed

72.

Gould J. The cannabis crop. Nature 2015; 525: S2-3.CrossRefPubMed

73.

Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182: E694-701.CrossRefPubMedPubMedCentral

74.

Page J, Ware M. Perspective: close the knowledge gap. Nature 2015; 525: S9.CrossRefPubMed

75.

Ware MA, Ziemianski D. Medical education on cannabis and cannabinoids: perspectives, challenges, and opportunities. Clin Pharmacol Ther 2015; 97: 548-50.CrossRefPubMed

76.

Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011; 4: 241-9.CrossRefPubMedPubMedCentral

Titel: Medical cannabis: considerations for the anesthesiologist and pain physician
verfasst von: Pierre Beaulieu, MD, PhD
Aline Boulanger, MD
Julie Desroches, PhD
Alexander J. Clark, MD
Publikationsdatum: 05.02.2016
Verlag: Springer US
Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Ausgabe 5/2016
Print ISSN: 0832-610X
Elektronische ISSN: 1496-8975
DOI: https://doi.org/10.1007/s12630-016-0598-x

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Medical cannabis: considerations for the anesthesiologist and pain physician

Abstract

Purpose

Source

Principal findings

Conclusion

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Abstract

Purpose

Source

Principal findings

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Dexmedetomidine during total knee arthroplasty performed under spinal anesthesia decreases opioid use: a randomized-controlled trial

Alpha-stat, beach chair, cerebral autoregulation… But who is at risk?

Epidural analgesia does not increase the rate of inpatient falls after major upper abdominal and thoracic surgery: a retrospective case-control study

Tracheal obstruction in a child with a posterior mediastinal mass

Failed caudal block due to physiologic changes associated with a cerebrospinal fluid leak: a case report

Traumatic lung herniation

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS